Glenmark to outlicense one molecule in FY10

Glenmark to outlicense one molecule in FY10

New Delhi : India | Dec 22, 2009 at 9:42 PM PST
Source: Daily News & Analysis
Views: Pending
It is also looking to outlicense phase 2-b trials Oglemilast. According to an analyst covering the company, outlicensing of Melogliptin and launch of Crofelmer (for HIV-related diarrhoea), which is a phase 3 candidate, are focus areas for Glenmark. A successful launch of Crofelmer can add $20-25... FULL ARTICLE AT Daily News & Analysis
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
  • Credibility
  • Wait... Flag

News Stories

  • Maruti to show India-made SUV concept

      Daily News & Analysis
    This is the first concept car developed entirely by Indian engineers -- all other cars in the Maruti portfolio were born in Japan. Only during the development of 'Swift' did some Indian engineers travel to Japan to assist in product development.
  • Maruti's new vehicle to launch on January 7

      Daily News & Analysis
    January 7, a senior executive said on Wednesday. The vehicle, available in 5-seater and 7-seater versions, is expected to initially sell 40,000 units annually, chief general manager of Marketing, Shashank Srivastava told reporters. Double click an...
  • Maruti to showcase 17 vehicles in Auto Expo

      Asian Age
    In a show of stre-ngth, the country’s largest carmaker Maruti Suzuki gears up to showcase 17 ve-hicles, including new laun-ches, at Delhi Auto Expo 2010 to be held in January. According to sources, the company will strengthen its family car segment...

More From Allvoices

Most Commented Reports

Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.